Ngā hua rapu - Persson, Frederik
- E whakaatu ana i te 1 - 20 hua o te 55
- Haere ki te Whārangi Whai Ake
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review mā Persson, Frederik, Lindhardt, Morten, Rossing, Peter, Parving, Hans-Henrik
I whakaputaina 2016Text -
9
-
10
Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture mā Rossing, Peter, Persson, Frederik, Frimodt-Møller, Marie, Hansen, Tine Willum
I whakaputaina 2021Text -
11
Discrepancy Between Tonometric Ambulatory and Cuff‐Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes mā Theilade, Simone, Lajer, Maria, Joergensen, Christel, Persson, Frederik, Rossing, Peter
I whakaputaina 2012Text -
12
YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria mā Rathcke, Camilla Noelle, Persson, Frederik, Tarnow, Lise, Rossing, Peter, Vestergaard, Henrik
I whakaputaina 2009Text -
13
-
14
-
15
Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy mā Persson, Frederik, Lewis, Julia B., Lewis, Edmund J., Rossing, Peter, Hollenberg, Norman K., Parving, Hans-Henrik
I whakaputaina 2010Text -
16
Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy mā Persson, Frederik, Lewis, Julia B., Lewis, Edmund J., Rossing, Peter, Hollenberg, Norman K., Parving, Hans-Henrik
I whakaputaina 2011Text -
17
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function mā Petrykiv, Sergei, Sjöström, C. David, Greasley, Peter J., Xu, John, Persson, Frederik, Heerspink, Hiddo J.L.
I whakaputaina 2017Text -
18
Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes – A comparative study of two ma... mā Broedbaek, Kasper, Køster-Rasmussen, Rasmus, Siersma, Volkert, Persson, Frederik, Poulsen, Henrik E., de Fine Olivarius, Niels
I whakaputaina 2017Text -
19
Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment mā Zobel, Emilie H., von Scholten, Bernt J., Goldman, Bryan, Persson, Frederik, Hansen, Tine W., Rossing, Peter
I whakaputaina 2019Text -
20
Importance of standardizing renal outcomes in clinical trials: illustration by recent SGLT2 inhibitor studies mā van Raalte, Daniël H., Bjornstad, Petter, Heerspink, Hiddo J.L., Persson, Frederik, Cherney, David Z.I.
I whakaputaina 2021Text